|
|
|
Insider
Information: |
Mario Ernest |
Relationship: |
Director |
City: |
Redwood City |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
13 |
|
Direct
Shares |
1,089,697 |
|
Indirect Shares
|
264,473 |
|
|
Direct
Value |
$8,309,557 |
|
|
Indirect Value
|
$120,004 |
|
|
Total
Shares |
1,354,170 |
|
|
Total
Value |
$8,429,560 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
3
|
0
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
2
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
-41.7%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Maxygen Inc |
MAXY |
Director |
2012-06-06 |
62,964 |
2003-08-05 |
0 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director |
2004-05-05 |
70,431 |
2004-05-05 |
85,554 |
Premium* |
|
Pharmaceutical Product Developme... |
PPDI |
Director |
2011-12-05 |
0 |
2011-12-05 |
0 |
Premium* |
|
Boston Scientific Corp |
BSX |
Director |
2015-11-16 |
86,032 |
2013-11-08 |
0 |
Premium* |
|
Alexza Pharmaceuticals Inc. |
ALXA |
Director |
2006-03-08 |
18,181 |
|
0 |
Premium* |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Vivus Inc |
VVUS |
Director |
2013-05-29 |
81,125 |
2012-04-25 |
0 |
Premium* |
|
Xenoport Inc |
XNPT |
Director |
2015-05-19 |
88,750 |
2012-08-09 |
0 |
Premium* |
|
Tonix Pharmaceuticals Holding Corp |
TNXP |
Director |
2018-02-09 |
0 |
2018-06-25 |
50,000 |
Premium* |
|
Chimerix Inc |
CMRX |
Director |
2018-05-18 |
12,905 |
2018-05-18 |
108,167 |
Premium* |
|
Kindred Biosciences, Inc. |
KIN |
Director |
2018-10-29 |
169,000 |
2013-12-12 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
Director |
2024-01-08 |
124,566 |
2024-01-08 |
20,752 |
Premium* |
|
Eyenovia Inc |
EYEN |
Director |
2021-01-15 |
375,743 |
2018-07-24 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
372 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 15
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CELG |
Celgene Corp |
Director |
|
2010-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
685 |
23,185 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2010-08-09 |
4 |
S |
$25.12 |
$671,357 |
D/D |
(26,726) |
160,433 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2010-11-04 |
4 |
B |
$6.44 |
$64,393 |
D/D |
10,000 |
81,004 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2010-12-06 |
4 |
B |
$55.00 |
$55,000 |
D/D |
1,000 |
24,185 |
2.39 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2010-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
172,933 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2010-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
12,500 |
275,653 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2010-12-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(25,000) |
6,000 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,355 |
175,288 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-02-07 |
4 |
B |
$6.94 |
$346,990 |
D/D |
50,000 |
131,004 |
2.39 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
32,916 |
208,204 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-03-14 |
4 |
A |
$0.00 |
$0 |
I/I |
32,916 |
308,569 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-03-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(65,832) |
58,244 |
0 |
- |
|
CELG |
Celgene Corp |
Director |
|
2011-03-15 |
4 |
B |
$53.33 |
$133,320 |
D/D |
2,500 |
36,685 |
2.39 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-04-05 |
4 |
GA |
$0.00 |
$0 |
D/D |
5,000 |
213,204 |
0 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-05-13 |
4 |
B |
$6.72 |
$14,972 |
I/I |
2,228 |
22,228 |
2.1 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-05-17 |
4 |
B |
$6.72 |
$1,828 |
I/I |
272 |
22,500 |
2.02 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,139 |
214,570 |
0 |
- |
|
MAXY |
Maxygen Inc |
Director |
|
2011-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
52,964 |
0 |
- |
|
CELG |
Celgene Corp |
Director |
|
2011-06-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
685 |
37,370 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
Director |
|
2011-06-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
115,500 |
193,069 |
0 |
- |
|
CELG |
Celgene Corp |
Director |
|
2011-08-01 |
4 |
B |
$58.10 |
$290,498 |
D/D |
5,000 |
42,370 |
2.39 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-08-02 |
4 |
B |
$6.82 |
$682,230 |
D/D |
100,000 |
231,004 |
2.39 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-08-03 |
4 |
B |
$6.70 |
$670 |
I/I |
100 |
22,600 |
2.02 |
- |
|
BSX |
Boston Scientific Corp |
Director |
|
2011-10-25 |
4 |
B |
$5.50 |
$137,500 |
D/D |
25,000 |
256,004 |
2.39 |
- |
|
CELG |
Celgene Corp |
Director |
|
2011-11-02 |
4 |
A |
$63.00 |
$126,000 |
D/D |
2,000 |
44,370 |
0 |
- |
|
372 Records found
|
|
Page 5 of 15 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|